Cargando…

B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders

Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanguay, Mégane, Boutin, Marianne, Laumaea, Annemarie, Salaciak, Matthew, Mendoza, Alma, Cassis, Chantal, Ajjamada, Lissa, Assouline, Sarit, Patenaude, François, Clark, Michael Webster, Finzi, Andrés, Johnson, Nathalie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784616/
https://www.ncbi.nlm.nih.gov/pubmed/35105492
http://dx.doi.org/10.1016/j.vaccine.2022.01.040
_version_ 1784638780259434496
author Tanguay, Mégane
Boutin, Marianne
Laumaea, Annemarie
Salaciak, Matthew
Mendoza, Alma
Cassis, Chantal
Ajjamada, Lissa
Assouline, Sarit
Patenaude, François
Clark, Michael Webster
Finzi, Andrés
Johnson, Nathalie A.
author_facet Tanguay, Mégane
Boutin, Marianne
Laumaea, Annemarie
Salaciak, Matthew
Mendoza, Alma
Cassis, Chantal
Ajjamada, Lissa
Assouline, Sarit
Patenaude, François
Clark, Michael Webster
Finzi, Andrés
Johnson, Nathalie A.
author_sort Tanguay, Mégane
collection PubMed
description Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 controls, 22 lymphoma patients on observation (cohort 1) and 55 lymphoma patients receiving their vaccines post B-cell depleting therapy (cohort 2). Half of the lymphoma patients in both cohorts achieved seropositivity compared to 100% of controls. In cohort 2, only 5% achieved an antibody response in the first year post B-cell depleting treatment, vs 88% treated >2 years prior. Also, 28% of patients with <50 B cells/µl achieved a serologic response vs 86% of patients with B-cell >50 B cells/µl. B-cell cytopenia is profound within the first year of exposure to B-cell depleting treatment, therefore an additional dose of vaccine within that timeframe is unlikely to raise antibody levels.
format Online
Article
Text
id pubmed-8784616
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-87846162022-01-24 B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders Tanguay, Mégane Boutin, Marianne Laumaea, Annemarie Salaciak, Matthew Mendoza, Alma Cassis, Chantal Ajjamada, Lissa Assouline, Sarit Patenaude, François Clark, Michael Webster Finzi, Andrés Johnson, Nathalie A. Vaccine Short Communication Patients with B-non-Hodgkin lymphoma (NHL) are at increased risk of morbidity and mortality from SARS-CoV-2. We investigated the relationship between B cell cytopenia and the SARS-CoV-2 vaccine response in B-NHL patients. We measured anti-RBD antibodies and the lymphocyte immunophenotype in 19 controls, 22 lymphoma patients on observation (cohort 1) and 55 lymphoma patients receiving their vaccines post B-cell depleting therapy (cohort 2). Half of the lymphoma patients in both cohorts achieved seropositivity compared to 100% of controls. In cohort 2, only 5% achieved an antibody response in the first year post B-cell depleting treatment, vs 88% treated >2 years prior. Also, 28% of patients with <50 B cells/µl achieved a serologic response vs 86% of patients with B-cell >50 B cells/µl. B-cell cytopenia is profound within the first year of exposure to B-cell depleting treatment, therefore an additional dose of vaccine within that timeframe is unlikely to raise antibody levels. Elsevier Ltd. 2022-02-23 2022-01-24 /pmc/articles/PMC8784616/ /pubmed/35105492 http://dx.doi.org/10.1016/j.vaccine.2022.01.040 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Tanguay, Mégane
Boutin, Marianne
Laumaea, Annemarie
Salaciak, Matthew
Mendoza, Alma
Cassis, Chantal
Ajjamada, Lissa
Assouline, Sarit
Patenaude, François
Clark, Michael Webster
Finzi, Andrés
Johnson, Nathalie A.
B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
title B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
title_full B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
title_fullStr B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
title_full_unstemmed B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
title_short B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
title_sort b-cell cytopenia and time to last b-cell-depleting therapy predict response to sars-cov-2 vaccines in patients with lymphoproliferative disorders
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784616/
https://www.ncbi.nlm.nih.gov/pubmed/35105492
http://dx.doi.org/10.1016/j.vaccine.2022.01.040
work_keys_str_mv AT tanguaymegane bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT boutinmarianne bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT laumaeaannemarie bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT salaciakmatthew bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT mendozaalma bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT cassischantal bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT ajjamadalissa bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT assoulinesarit bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT patenaudefrancois bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT clarkmichaelwebster bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT finziandres bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders
AT johnsonnathaliea bcellcytopeniaandtimetolastbcelldepletingtherapypredictresponsetosarscov2vaccinesinpatientswithlymphoproliferativedisorders